Skip to main content

Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter Results on July 20, 2022

Elevance Health (NYSE: ELV) will release second quarter 2022 financial results on July 20, 2022, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:

888-947-9963 (Domestic)

866-430-8797 (Domestic Replay)

312-470-0178 (International)

203-369-0943 (International Replay)

The access code for the call is 3972058. There is no access code for the replay. The replay will be available from 11:30 a.m. EDT on July 20, 2022 until the end of the day on August 20, 2022. The call will also be available through a live webcast at www.elevancehealth.com under the “Investors” link. A webcast replay will be available following the call.

About Elevance Health, Inc.

Elevance Health is a lifetime, trusted health partner fueled by its purpose to improve the health of humanity. The company supports consumers, families, and communities across the entire care journey – connecting them to the care, support, and resources they need to lead healthier lives. Elevance Health’s companies serve more than 118 million people through a diverse portfolio of industry-leading medical, digital, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on Twitter and Elevance Health on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  237.82
-5.19 (-2.14%)
AAPL  255.65
-0.79 (-0.31%)
AMD  243.78
-8.96 (-3.54%)
BAC  52.39
+0.58 (1.12%)
GOOG  329.87
-6.41 (-1.91%)
META  718.27
+49.54 (7.41%)
MSFT  421.99
-59.64 (-12.38%)
NVDA  187.28
-4.24 (-2.21%)
ORCL  164.22
-8.58 (-4.97%)
TSLA  421.07
-10.39 (-2.41%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.